(Q37828538)

24 August 2017

1 reference

title

Developments in antivirals against influenza, smallpox and hemorrhagic fever viruses (English)

1 reference

24 August 2017

1 reference

Kylene Kehn-Hall

4

0 references

Fatah Kashanchi

series ordinal

3

object named as

Fatah Kashanchi

1 reference

24 August 2017

Aarthi Narayanan

1

1 reference

24 August 2017

Charles Bailey

series ordinal

2

1 reference

24 August 2017

language of work or name

English

0 references

publication date

1 February 2011

1 reference

Expert Opinion on Investigational Drugs

24 August 2017

published in

1 reference

24 August 2017

volume

20

1 reference

24 August 2017

issue

2

1 reference

24 August 2017

page(s)

239-254

1 reference

Antiviral agents active against influenza A viruses.

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

ANTIVIRAL ACTIVITY OF 1-ADAMANTANAMINE (AMANTADINE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Obstructive acute renal failure related to amantadine intoxication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Mutations of neuraminidase implicated in neuraminidase inhibitors resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Person-to-person transmission of oseltamivir-resistant influenza A/H1N1 viruses in two households; Germany 2007/08.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Assessing the development of oseltamivir and zanamivir resistance in A(H5N1) influenza viruses using a ferret model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Neuraminidase inhibitors in patients with underlying airways disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Synthesis and anti-influenza evaluation of orally active bicyclic ether derivatives related to zanamivir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Peramivir and its use in H1N1 influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

An O-glycoside of sialic acid derivative that inhibits both hemagglutinin and sialidase activities of influenza viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Natural and synthetic sialic acid-containing inhibitors of influenza virus receptor binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Chemoenzymatic synthesis and application of glycopolymers containing multivalent sialyloligosaccharides with a poly(L-glutamic acid) backbone for inhibition of infection by influenza viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Simple synthesis of sialyllactose-carrying polystyrene and its binding with influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Sialic acid-mimic peptides as hemagglutinin inhibitors for anti-influenza therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Interplay between influenza A virus and the innate immune signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Mutations in the NS1 protein of swine influenza virus impair anti-interferon activity and confer attenuation in pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Novel influenza virus NS1 antagonists block replication and restore innate immune function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

T-705 (favipiravir) activity against lethal H5N1 influenza A viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Inhibition of highly pathogenic avian influenza virus H5N1 replication by the small interfering RNA targeting polymerase A gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Mesoionic heterocyclic compounds as candidate messenger RNA cap analogue inhibitors of the influenza virus RNA polymerase cap-binding activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

In vitro and in vivo influenza virus-inhibitory effects of viramidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Active NF-kappaB signalling is a prerequisite for influenza virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Protection from the 2009 H1N1 pandemic influenza by an antibody from combinatorial survivor-based libraries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

An antibody against a novel and conserved epitope in the hemagglutinin 1 subunit neutralizes numerous H5N1 influenza viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Effect of 1-beta-D-ribofuranosyl1-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) on herpes and vaccinia keratitis and encephalitis in laboratory animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Antiviral activities of 5-ethynyl-1-beta-D-ribofuranosylimidazole-4- carboxamide and related compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Broad-spectrum antiviral activity of the carbocyclic analog of 3-deazaadenosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

9-(trans-2',trans-3'-Dihydroxycyclopent-4'-enyl)-adenine and -3-deazaadenine: analogs of neplanocin A which retain potent antiviral activity but exhibit reduced cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Progress in the discovery of compounds inhibiting orthopoxviruses in animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

The acyclic nucleoside phosphonates from inception to clinical use: historical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Cidofovir inhibits genome encapsidation and affects morphogenesis during the replication of vaccinia virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Mousepox in the C57BL/6 strain provides an improved model for evaluating anti-poxvirus therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

In vitro and in vivo evaluation of isatin-beta-thiosemicarbazone and marboran against vaccinia and cowpox virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Amino acid substitutions at multiple sites within the vaccinia virus D13 scaffold protein confer resistance to rifampicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Toxicity of the topoisomerase II inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Drug therapy for acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Mitoxantrone: benefits and risks in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Identification of novel antipoxviral agents: mitoxantrone inhibits vaccinia virus replication by blocking virion assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Tecovirimat for smallpox infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Novel therapeutic agents against cancer stem cells of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Tyrosine kinase blockers: new hope for successful cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Hemorrhagic fever viruses as biological weapons: medical and public health management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Ebolavirus and Marburgvirus: insight the Filoviridae family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Prospects for immunisation against Marburg and Ebola viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

The highly specific carbohydrate-binding protein cyanovirin-N: structure, anti-HIV/Ebola activity and possibilities for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

In vitro evaluation of cyanovirin-N antiviral activity, by use of lentiviral vectors pseudotyped with filovirus envelope glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Cyanovirin-N binds to the viral surface glycoprotein, GP1,2 and inhibits infectivity of Ebola virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Neutralizing ebolavirus: structural insights into the envelope glycoprotein and antibodies targeted against it

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Ebolavirus glycoprotein structure and mechanism of entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Oligomerization of Ebola virus VP30 is essential for viral transcription and can be inhibited by a synthetic peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Oligonucleotide antiviral therapeutics: antisense and RNA interference for highly pathogenic RNA viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Advanced antisense therapies for postexposure protection against lethal filovirus infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Inhibition of Marburg virus protein expression and viral release by RNA interference

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

In vitro evaluation of antisense RNA efficacy against filovirus infection, by use of reverse genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Antiviral drug therapy of filovirus infections: S-adenosylhomocysteine hydrolase inhibitors inhibit Ebola virus in vitro and in a lethal mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Antiviral properties of deazaadenine nucleoside derivatives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

3-deazaneplanocin A induces massively increased interferon-alpha production in Ebola virus-infected mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Antiviral activity of a small-molecule inhibitor of filovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Development of a broad-spectrum antiviral with activity against Ebola virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Identification of essential filovirion-associated host factors by serial proteomic analysis and RNAi screen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Arenaviruses other than Lassa virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Genetic detection and characterization of Lujo virus, a new hemorrhagic fever-associated arenavirus from southern Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Chapare virus, a newly discovered arenavirus isolated from a fatal hemorrhagic fever case in Bolivia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Candid No. 1 Argentine hemorrhagic fever vaccine protects against lethal Junin virus challenge in rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. AHF Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Exotic emerging viral diseases: progress and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Ribavirin prophylaxis and therapy for experimental argentine hemorrhagic fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Myristoylation of the RING finger Z protein is essential for arenavirus budding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Myristic acid analogs are inhibitors of Junin virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

The role of myristoylation in the membrane association of the Lassa virus matrix protein Z.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

An antiviral disulfide compound blocks interaction between arenavirus Z protein and cellular promyelocytic leukemia protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Characterization of Junín virus particles inactivated by a zinc finger-reactive compound

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Arenavirus Z protein as an antiviral target: virus inactivation and protein oligomerization by zinc finger-reactive compounds.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Inhibition of arenavirus infection by thiuram and aromatic disulfides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Inhibition of Junín virus replication by small interfering RNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Identification and characterization of potent small molecule inhibitor of hemorrhagic fever New World arenaviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

pH-induced activation of arenavirus membrane fusion is antagonized by small-molecule inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Identification of a broad-spectrum arenavirus entry inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

In Vitro and In Vivo Activities of T-705 against Arenavirus and Bunyavirus Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Targeting the proteolytic processing of the viral glycoprotein precursor is a promising novel antiviral strategy against arenaviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

PI3K-Akt signaling and viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Participation of the phosphatidylinositol 3-kinase/Akt pathway in Junín virus replication in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Genistein treatment of cells inhibits arenavirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Treatment of Crimean-Congo hemorrhagic fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

The efficacy of ribavirin in the treatment of Crimean-Congo hemorrhagic fever in Eastern Black Sea region in Turkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Rift Valley fever virus vaccine trial: study of neutralizing antibody response in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Rift valley fever vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

A broad-spectrum antiviral targeting entry of enveloped viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Prophylactic and therapeutic intervention of Punta Toro virus (Phlebovirus, Bunyaviridae) infection in hamsters with interferon alfacon-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Efficacy of favipiravir (T-705) and T-1106 pyrazine derivatives in phlebovirus disease models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

beta3 Integrins mediate the cellular entry of hantaviruses that cause respiratory failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Peptide antagonists that inhibit Sin Nombre virus and hantaan virus entry through the beta3-integrin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Characterization and NMR solution structure of a novel cyclic pentapeptide inhibitor of pathogenic hantaviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Phase I evaluation of the safety and pharmacokinetics of a single-dose intravenous injection of a murine monoclonal antibody against Hantaan virus in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Production and characterization of a recombinant single-chain antibody against Hantaan virus envelop glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

21 January 2018

Emerging antiviral drugs

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

Targeting cell signalling pathways to fight the flu: towards a paradigm change in anti-influenza therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.547852

10.1517/13543784.2011.547852

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference